Form 4: Marinus Pharmaceuticals Director Sells Shares to Cover Tax Obligations

Director Marvin Johnson sold 1,610 shares of Marinus Pharmaceuticals common stock at $0.54 per share on January 21, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• On January 21, 2025, Marvin Johnson, a director of Marinus Pharmaceuticals, sold 1,610 shares of common stock.
• The sale price was $0.54 per share.
• The transaction was executed under a pre-arranged Rule 10b5-1 plan adopted on March 10, 2024.
• The purpose of the sale was to cover tax obligations associated with the vesting of restricted stock units.
• Following the transaction, Johnson directly owns 12,490 shares of Marinus Pharmaceuticals.
• The sale was reported on Form 4 filed with the SEC on January 23, 2025.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale to cover taxes) by a company director under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Sales by company directors are a normal part of business, especially when related to tax obligations. The use of a 10b5-1 plan indicates the director planned the sale in advance.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder confidence, but the pre-planned nature of the sale mitigates this.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Marvin Johnson, stock sale, Form 4, Rule 10b5-1, director, insider trading, tax obligations, restricted stock units